Amondys 45 Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Amondys 45 market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historical period can be attributed to the increasing prevalence of Duchenne muscular dystrophy, heightened awareness of rare diseases, regulatory approvals of RNA-based drugs, greater availability of personalized medicine, and strong patient advocacy efforts.

The projected growth during the forecast period is driven by a growing demand for targeted treatments, rising healthcare spending, supportive government policies, the expansion of clinical trials for DMD, and advancements in genetic disorder diagnostics. Key trends in the forecast period include a shift towards precision medicine, the rise of combination therapies, the growing adoption of gene-editing technologies, the integration of AI in drug development, and an increase in biosimilar advancements.

The increasing prevalence of duchenne muscular dystrophy (DMD) is expected to drive the growth of the amondys 45 market in the coming years. DMD is a genetic disorder characterized by progressive muscle weakness and degeneration, primarily affecting boys, caused by a lack of dystrophin protein. The rise in DMD cases is attributed to factors such as improved diagnosis, heightened awareness, better reporting and record-keeping, advancements in genetic testing, and more recognition of symptoms. Amondys 45 addresses this growing prevalence by offering targeted therapy for patients with a specific genetic mutation (exon 45). For example, in February 2022, the National Institutes of Health (NIH) estimated the global prevalence of muscular dystrophy at 3.6 per 100,000 people, with the highest prevalence in the Americas at 5.1 per 100,000 people. As a result, the growing prevalence of DMD is contributing to the expansion of the amondys 45 market.

The increase in healthcare expenditure is expected to further accelerate the growth of the amondys 45 market. Healthcare expenditure refers to the total financial resources allocated to healthcare services, including medical treatment, infrastructure, and programs. Several factors drive this rise, including an aging population, advancements in medical technology, an increase in chronic diseases, inflation, rising medical supply costs, and higher expectations for quality care. Amondys 45 plays a role in rising healthcare costs by providing a specialized treatment for DMD, which requires significant investment in advanced therapies and continuous healthcare services while improving patient outcomes. For example, a May 2024 report from the Office for National Statistics in the UK showed a 5.6% increase in healthcare expenditure between 2022 and 2023, compared to just 0.9% growth in 2022. This rise in healthcare spending is fueling the growth of the amondys 45 market.

A significant trend in the amondys 45 market is the development of innovative targeted therapies for Duchenne muscular dystrophy (DMD), aimed at improving muscle health by increasing dystrophin production in patients with specific genetic mutations. Targeted DMD treatments focus on restoring or enhancing the function of dystrophin to improve muscle integrity and function. For example, the U.S. Food and Drug Administration (FDA) approved Amondys 45 (casimersen) injection for treating DMD in patients with a confirmed genetic mutation suitable for exon 45 skipping. This approval marks the first FDA-approved targeted therapy for this specific mutation and represents a significant advance in personalized medicine for DMD patients. Clinical evidence supporting this treatment showed increased dystrophin production, which is essential for muscle health, offering hope to patients and reinforcing the need for specialized therapies for rare genetic disorders.

The key company operating in the amondys 45 market is Sarepta Therapeutics Inc.

North America was the largest region in the amondys 45 market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in amondys 45 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the amondys 45 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Amondys 45 (casimersen) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the DMD gene that is responsive to exon 45 skipping. This therapy is an antisense oligonucleotide that works by targeting and skipping exon 45 during gene transcription, which helps produce a functional, though shortened, dystrophin protein.

The primary indications for amondys 45 are Duchenne muscular dystrophy (DMD) with an exon 45 mutation and other related genetic mutations. DMD with an exon 45 mutation is a genetic form of the condition caused by a mutation in the DMD gene that affects exon 45, resulting in a deficiency of dystrophin, a protein crucial for muscle cell integrity and function. The medication is used by adults, geriatric patients, and pediatric patients, and it is distributed through hospitals, retail pharmacies, and online pharmacies.

The amondys 45 market research report is one of a series of new reports that provides amondys 45 market statistics, including amondys 45 industry global market size, regional shares, competitors with a amondys 45 market share, detailed amondys 45 market segments, market trends and opportunities, and any further data you may need to thrive in the amondys 45 industry. This amondys 45 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The amondys 45 market consists of sales of injectable solutions and antisense oligonucleotide products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.